Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.38 |
| ▸ | MAOA | P21397 | 3/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.34 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20554314 | 0.88 | SLC6A4 (0.38) | MAOBMAOAGRM5RAB9AL3MBTL1 | |
| SCHEMBL20554850 | 0.85 | MAOB (0.45) | MAOBMAOAGRM5RAB9ALTB4R | |
| SCHEMBL30132570 | 0.85 | MAOB (0.45) | MAOBMAOAGRM5RAB9ALTB4R | |
| SCHEMBL20554264 | 0.84 | RAB9A (0.40) | MAOBMAOARAB9AL3MBTL1LTB4R | |
| SCHEMBL20554131 | 0.84 | MAOB (0.36) | MAOBMAOAGRM5RAB9A | |
| SCHEMBL30665359 | 0.79 | LMNA (0.38) | MAOBMAOAGRM5LTB4RLTB4R2 | |
| SCHEMBL26615220 | 0.79 | LMNA (0.38) | MAOBMAOAGRM5LTB4RLTB4R2 | |
| SCHEMBL30132637 | 0.75 | MAOB (0.52) | MAOBMAOAGRM5RAB9A | |
| SCHEMBL20554219 | 0.75 | MAOB (0.52) | MAOBMAOAGRM5RAB9A | |
| SCHEMBL13506258 | 0.74 | MAOB (0.38) | MAOBMAOAGRM5LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110770211-B | Alpha, beta unsaturated amide compound | 协和麒麟株式会社 | 2023-09-19 | — | — | CN | disclosed |
| CN-108430972-B | Alpha, beta-unsaturated amide compound | 协和麒麟株式会社 | 2022-12-27 | — | — | CN | disclosed |
| US-11447471-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2022-09-20 | — | — | US | disclosed |
| US-11332455-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2022-05-17 | — | — | US | disclosed |
| US-20210380551-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2021-12-09 | — | — | US | disclosed |
| US-20210155612-A1 | Alpha,Beta-UNSATURATED AMIDE COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2021-05-27 | — | — | US | disclosed |
| US-10787428-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2020-09-29 | — | — | US | disclosed |
| EP-3712129-A1 | ALPHA, BETA-UNSATURATED AMIDE COMPOUND | Kyowa Kirin Co., Ltd. (JP) | 2020-09-23 | — | — | EP | disclosed |
| CN-110770211-A | α unsaturated amide compound | 协和麒麟株式会社 | 2020-02-07 | — | — | CN | disclosed |
| US-20190010136-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-01-10 | — | — | US | disclosed |
| EP-3401309-A1 | a, ß UNSATURATED AMIDE COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2018-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155612-A1 | Alpha,Beta-UNSATURATED AMIDE COMPOUND | NR1H2, NR1H3, RXRA | MAOB 3240/4885MAOA 3301/4885GRM5 1244/4885 |
| US-11447471-B2 | α,β-unsaturated amide compound | NR1H2, RXRA, RXRB | MAOB 3184/4885MAOA 3131/4885GRM5 1075/4885 |
| US-10787428-B2 | α,β-unsaturated amide compound | NR1H2, NCOA1, NR0B1 | MAOB 3552/4885MAOA 3332/4885GRM5 1006/4885 |
| US-20210380551-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | NR1H2, NR1H3, NCOA1 | MAOB 3686/4885MAOA 3585/4885GRM5 1212/4885 |
| US-11332455-B2 | α,β-unsaturated amide compound | NR1H2, NCOA1, NR0B1 | MAOB 3552/4885MAOA 3332/4885GRM5 1006/4885 |
| US-20190010136-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | NR1H2, NR1H3, NCOA1 | MAOB 3686/4885MAOA 3585/4885GRM5 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.